News

Stivarga® (regorafenib) is reimbursed in Belgium

On 1 july  2015, Stivarga® (regorafenib) is reimbursed in Belgium.  

Stivarga® is an oral drug that can be prescribed for the treatment of chemorefractory metastastic colorectal cancer as well as metastatic gastrointestinal stromal tumors (GIST) refractory or intolerant to imatinib and sunitinib . 

Read more